Financial ConstraintsNRSN finished with $3.4M in cash and equivalents, which is not sufficient to fund the Phase 3 trial.
Funding ChallengesCapital constraints, including 'baby shelf' limitations, make it difficult to raise sufficient capital to fully finance the Phase 3 trial.
Regulatory ChallengesShares are downgraded to Hold due to the unlikelihood of pursuing an Accelerated Approval pathway in the U.S. for PrimeC.